Page 2326 - Williams Hematology ( PDFDrive )

2300 Part XII: Hemostasis and Thrombosis Chapter 134: Atherothrombosis: Disease Initiation, Progression, and Treatment 2301

107. Shaw PX, Horkko S, Chang MK, et al: Natural antibodies with the T15 idiotype may 138. Cipollone F, Mezzetti A, Porreca E, et al: Association between enhanced soluble CD40L
act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest and prothrombotic state in hypercholesterolemia effects of statin therapy. Circulation
105:1731–1740, 2000. 106:399–402, 2002.
108. Tsimikas S, Palinski W, Witztum JL: Circulating autoantibodies to oxidized LDL 139. Mallat Z, Gojova A, Marchiol-Fournigault C, et al: Inhibition of transforming growth
correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor- factor-beta signaling accelerates atherosclerosis and induces an unstable plaque pheno-
deficient mice. Arterioscler Thromb Vasc Biol 21:95–100, 2001. type in mice. Circ Res 89:930–934, 2001.
109. Palinski W, Ord VA, Plump AS, et al: ApoE-deficient mice are a model of lipoprotein 140. Zhang H, Mooney CJ, Reilly MP: ABO blood groups and cardiovascular diseases. Int J
oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and Vasc Med 2012:641917, 2012.
high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 141. Gurfinkel E, Lernoud V: The role of infection and immunity in atherosclerosis. Expert
14:605–616, 1994. Rev Cardiovasc Ther 4:131–137, 2006.
110. Ameli S, Hultgardh-Nilsson A, Regnstrom J, et al: Effect of immunization with homol- 142. Ford PJ, Yamazaki K, Seymour GJ: Cardiovascular and oral disease interactions: What
ogous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. is the evidence? Prim Dent Care 14:59–66, 2007.
Arterioscler Thromb Vasc Biol 16:1074–1079, 1996. 143. Mayr M, Kiechl S, Willeit J, et al: Infections, immunity, and atherosclerosis: Associa-
111. Freigang S, Horkko S, Miller E, et al: Immunization of LDL receptor-deficient mice tions of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus
with homologous malondialdehyde-modified and native LDL reduces progression of with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis.
atherosclerosis by mechanisms other than induction of high titers of antibodies to oxi- Circulation 102:833–839, 2000.
dative neoepitopes. Arterioscler Thromb Vasc Biol 18:1972–1982, 1998. 144. Caligiuri G, Nicoletti A, Poirier B, Hansson GK: Protective immunity against athero-
112. Zhou X, Caligiuri G, Hamsten A, et al: LDL immunization induces T-cell-dependent sclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109:745–753,
antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc 2002.
Biol 21:108–114, 2001. 145. Robinette CD, Fraumeni JF Jr: Splenectomy and subsequent mortality in veterans of the
113. Mehrabian M, Allayee H, Wong J, et al: Identification of 5-lipoxygenase as a major gene 1939–45 war. Lancet 2:127–129, 1977.
contributing to atherosclerosis susceptibility in mice. Circ Res 91:120–126, 2002. 146. Yamada Y, Ichihara S, Nishida T: Molecular genetics of myocardial infarction. Genomic
114. Cyrus T, Witztum JL, Rader DJ, et al: Disruption of the 12/15-lipoxygenase gene dimin- Med 2:7–22, 2008.
ishes atherosclerosis in apo E-deficient mice. J Clin Invest 103:1597–1604, 1999. 147. Helgadottir A, Manolescu A, Thorleifsson G, et al: The gene encoding 5-lipoxygenase
115. Harats D, Shaish A, George J, et al: Overexpression of 15-lipoxygenase in vascular activating protein confers risk of myocardial infarction and stroke. Nat Genet 36:
endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterio- 233–239, 2004.
scler Thromb Vasc Biol 20:2100–2105, 2000. 148. Topol EJ, Smith J, Plow EF, Wang QK: Genetic susceptibility to myocardial infarction
116. Whatling C, McPheat W, Herslof M: The potential link between atherosclerosis and the and coronary artery disease. Hum Mol Genet 15 Spec No 2:R117–R123, 2006.
5-lipoxygenase pathway: Investigational agents with new implications for the cardio- 149. Helgadottir A, Thorleifsson G, Manolescu A, et al: A common variant on chromosome
vascular field. Expert Opin Investig Drugs 16:1879–1893, 2007. 9p21 affects the risk of myocardial infarction. Science 316:1491–1493, 2007.
117. Vinje S, Stroes E, Nieuwdorp M, Hazen SL: The gut microbiome as novel cardio- 150. Roberts R: Genetics of coronary artery disease. Circ Res 114:1890–1903, 2014.
metabolic target: The time has come! Eur Heart J 35:883–887, 2014. 151. Falk E: Plaque rupture with severe pre-existing stenosis precipitating coronary throm-
118. Williams KJ, Feig JE, Fisher EA: Cellular and molecular mechanisms for rapid regres- bosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive
sion of atherosclerosis: From bench top to potentially achievable clinical goal. Curr thrombi. Br Heart J 50:127–134, 1983.
Opin Lipidol 18:443–450, 2007. 152. Davies MJ, Thomas AC: Plaque fissuring—The cause of acute myocardial infarction,
119. Schwenke DC: Comparison of aorta and pulmonary artery: I. Early cholesterol accu- sudden ischaemic death, and crescendo angina. Br Heart J 53:363–373, 1985.
mulation and relative susceptibility to atheromatous lesions. Circ Res 81:338–345, 1997. 153. Muller JE: Circadian variation and triggering of acute coronary events. Am Heart J
120. Schwenke DC: Comparison of aorta and pulmonary artery: II. LDL transport and 137:S1–S8.
metabolism correlate with susceptibility to atherosclerosis. Circ Res 81:346–354, 1997. 154. Muller JE, Abela GS, Nesto RW, Tofler GH: Triggers, acute risk factors and vulnerable
121. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G: Association of apo B lipoproteins plaques: The lexicon of a new frontier. J Am Coll Cardiol 23:809–813, 1999, 1994.
with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis 155. Naghavi M, Libby P, Falk E, et al: From vulnerable plaque to vulnerable patient: A call
139:205–222, 1998. for new definitions and risk assessment strategies: Part I. Circulation 108:1664–1672,
122. Navab M, Hama SY, Reddy ST, et al: Oxidized lipids as mediators of coronary heart 2003.
disease. Curr Opin Lipidol 13:363–372, 2002. 156. Virmani R, Kolodgie FD, Burke AP, et al: Lessons from sudden coronary death: A com-
123. Rajavashisth TB, Andalibi A, Territo MC, et al: Induction of endothelial cell expression prehensive morphological classification scheme for atherosclerotic lesions. Arterioscler
of granulocyte and macrophage colony-stimulating factors by modified low-density Thromb Vasc Biol 20:1262–1275, 2000.
lipoproteins. Nature 344:254–257, 1990. 157. Casscells W, Naghavi M, Willerson JT: Vulnerable atherosclerotic plaque: A multifocal
124. Steinberg D: Atherogenesis in perspective: Hypercholesterolemia and inflammation as disease. Circulation 107:2072–2075, 2003.
partners in crime. Nat Med 8:1211–1217, 2002. 158. Uchida Y, Nakamura F, Tomaru T, et al: Prediction of acute coronary syndromes by per-
125. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 cutaneous coronary angioscopy in patients with stable angina. Am Heart J 130:195–203,
high-risk individuals: A randomised placebo-controlled trial. Lancet 360:23–33, 2002. 1995.
126. Brown BG, Zhao XQ, Chait A, et al: Simvastatin and niacin, antioxidant vitamins, or the 159. Ambrose JA: In search of the “vulnerable plaque”: Can it be localized and will focal
combination for the prevention of coronary disease. N Engl J Med 345:1583–1592, 2001. regional therapy ever be an option for cardiac prevention? J Am Coll Cardiol 51:
127. Tangirala RK, Tsukamoto K, Chun SH, et al: Regression of atherosclerosis induced by 1539–1542, 2008.
liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100:1816–1822, 160. Naghavi M, Libby P, Falk E, et al: From vulnerable plaque to vulnerable patient: A call
1999. for new definitions and risk assessment strategies: Part II. Circulation 108:1772–1778,
128. Zhang Y, Zanotti I, Reilly MP, et al: Overexpression of apolipoprotein A-I promotes 2003.
reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108: 161. Davi G, Patrono C: Platelet activation and atherothrombosis. N Engl J Med 357:
661–663, 2003. 2482–2494, 2007.
129. Khera AV, Cuchel M, de la Llera-Moya M, et al: Cholesterol efflux capacity, high-den- 162. Owens AP 3rd, Mackman N: Role of tissue factor in atherothrombosis. Curr Atheroscler
sity lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135, 2011. Rep 14:394–401, 2012.
130. Mineo C, Deguchi H, Griffin JH, Shaul PW: Endothelial and antithrombotic actions of 163. Frostegard J: Systemic lupus erythematosus and cardiovascular disease. Lupus 17:
HDL. Circ Res 98:1352–1364, 2006. 364–367, 2008.
131. Shih DM, Gu L, Xia YR, et al: Mice lacking serum paraoxonase are susceptible to 164. Rohla M, Weiss TW: Metabolic syndrome, inflammation and atherothrombosis. Hamo-
organophosphate toxicity and atherosclerosis. Nature 394:284–287, 1998. staseologie 33:283–294, 2013.
132. Haraguchi Y, Toh R, Hasokawa M, et al: Serum myeloperoxidase/paraoxonase 1 ratio as 165. Heo KS, Fujiwara K, Abe J: Shear stress and atherosclerosis. Mol Cells 37:435–440, 2014.
potential indicator of dysfunctional high-density lipoprotein and risk stratification in 166. Cosemans JM, Angelillo-Scherrer A, Mattheij NJ, Heemskerk JW: The effects of arte-
coronary artery disease. Atherosclerosis 234:288–294, 2014. rial flow on platelet activation, thrombus growth, and stabilization. Cardiovasc Res 99:
133. Barter PJ, Caulfield M, Eriksson M, et al: Effects of torcetrapib in patients at high risk 342–352, 2013.
for coronary events. N Engl J Med 357:2109–2122, 2007. 167. Aird WC: Vascular bed-specific thrombosis. J Thromb Haemost 5 Suppl 1:283–291,
134. Nissen SE, Tsunoda T, Tuzcu EM, et al: Effect of recombinant ApoA-I Milano on 2007.
coronary atherosclerosis in patients with acute coronary syndromes: A randomized 168. Chien S: Effects of disturbed flow on endothelial cells. Ann Biomed Eng 36:554–562,
controlled trial. JAMA 290:2292–2300, 2003. 2008.
135. Van Lenten BJ, Navab M, Anantharamaiah GM, et al: Multiple indications for anti- 169. Helderman F, Segers D, de Crom R, et al: Effect of shear stress on vascular inflammation
inflammatory apolipoprotein mimetic peptides. Curr Opin Investig Drugs 9:1157–1162, and plaque development. Curr Opin Lipidol 18:527–533, 2007.
2008. 170. Badimon JJ, Ortiz AF, Meyer B, et al: Different response to balloon angioplasty of
136. Rizvi M, Pathak D, Freedman JE, Chakrabarti S: CD40-CD40 ligand interactions in carotid and coronary arteries: Effects on acute platelet deposition and intimal thicken-
oxidative stress, inflammation and vascular disease. Trends Mol Med 14:530–538, 2008. ing. Atherosclerosis 140:307–314, 1998.
137. Zhang B, Wu T, Chen M, et al: The CD40/CD40L system: A new therapeutic target for 171. Halvorsen B, Otterdal K, Dahl TB, et al: Atherosclerotic plaque stability—What deter-
disease. Immunol Lett 153:58–61, 2013. mines the fate of a plaque? Prog Cardiovasc Dis 51:183–194, 2008.

Kaushansky_chapter 134_p2281-2302.indd 2300 17/09/15 3:50 pm